Checked
GT Biopharma, Inc.
Nasdaq: GTBP · Pharmaceutical Preparations · San Francisco, CA
- Net income
- -$28.35M
- Total assets
- $8.11M
- Diluted EPS
- -$6.68
Company details
As reported to the SEC
- SEC CIK
- 109657
- Stock
- Nasdaq: GTBP
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 505 Montgomery Street, 10th Floor, San Francisco, CA 94111
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (800) 304-9888
- Employer ID (EIN)
- 94-1620407
- Last annual report
- 03/02/2026
- Last quarterly report
- 08/14/2026
Formerly: OXIS INTERNATIONAL INC (until 07/25/2017)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Operating income | -$12.42M | -$14.36M | -$13.58M | -$21.26M | -$57.52M |
| Net income | -$28.35M | -$13.16M | -$7.6M | -$20.88M | -$58.01M |
| Diluted earnings per share | -$6.68 | -$6.94 | -$5.64 | -$19.66 | -$2.06 |
| Research and development | $3.47M | $5.8M | $6.47M | $8.81M | $9.59M |
| Total assets | $8.11M | $4.23M | $14.11M | $16.74M | $32.17M |
| Total liabilities | Not reported | Not reported | $6.63M | $5M | $10.26M |
| Shareholders' equity | $5.79M | -$1.67M | $7.48M | $11.73M | $21.91M |
| Cash and cash equivalents | $6.81M | $3.95M | $1.08M | $5.67M | $8.97M |
| Cash from operations | -$12.91M | -$12.9M | -$8.85M | -$15.22M | -$15.61M |
Recent filings
182 recent filings on record
Swipe the table sideways to see more columns.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is GT Biopharma, Inc.'s CIK number?
- GT Biopharma, Inc.'s SEC Central Index Key (CIK) is 109657.
- What is GT Biopharma, Inc.'s stock ticker?
- GT Biopharma, Inc. trades as Nasdaq: GTBP.
- When does GT Biopharma, Inc.'s fiscal year end?
- GT Biopharma, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is GT Biopharma, Inc. headquartered?
- GT Biopharma, Inc.'s principal executive office on file with the SEC is in San Francisco, CA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026